During the corresponding time, Day One Biopharmaceuticals Inc recorded a revenue increase by 83.92 % year on year, sequentially revenue grew by 34.99 %. While revenue at the Day One Biopharmaceuticals Inc 's corporate clients
Day One Biopharmaceuticals Inc's Comment on Sales, Marketing and Customers
The organization serves managed care, government payers, hospital systems, specialty distributors, specialty pharmacies, physicians, and patients. In the United States, pLGG is treated by a specialized group of specialists, supported by 18 sales representatives who call on approximately 200 accounts that treat over 90% of pLGG patients. Outside the United States, the company collaborates with Ipsen to distribute and commercialize OJEMDA, utilizing Ipsen's established teams and expertise in those markets. The company competes with pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and research institutions, some of which may have greater financial resources, market presence, and expertise in drug development and commercialization. Key competitive factors include efficacy, safety, and patient convenience.
News about Day One Biopharmaceuticals Inc Contracts
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric CancersDay One, a leading biotechnology company focused on developing innovative therapies for cancer and rare diseases, has recently announced the expansion of its pipeline with the potential first-in-class clinical-stage Antibody Drug Conjugate (ADC) targeting Protein Tyrosine Kinase-7 (PTK7). This novel ADC, named MTX-13 (DAY301), has received Investigational New Drug (IND) clearance by the U.S. Food and Drug Administration (FDA) in April 2024.Under an exclusive license agreement, Day One now has the rights for the development and commercialization of M...
Day One Biopharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The organization serves managed care, government payers, hospital systems, specialty distributors, specialty pharmacies, physicians, and patients. In the United States, pLGG is treated by a specialized group of specialists, supported by 18 sales representatives who call on approximately 200 accounts that treat over 90% of pLGG patients. Outside the United States, the company collaborates with Ipsen to distribute and commercialize OJEMDA, utilizing Ipsen's established teams and expertise in those markets. The company competes with pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and research institutions, some of which may have greater financial resources, market presence, and expertise in drug development and commercialization. Key competitive factors include efficacy, safety, and patient convenience.
Sources:
Day One Biopharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Day One Biopharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Day One Biopharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
